ALK (Anaplastic lymphoma kinase)

Stage III ALK-positive NSCLC is prone to relapse but local therapy combined with adjuvant ALK TKIs offers a promising strategy. Patients with EML4-ALK v1 mutations may show improved outcomes.

Understanding these dynamics is essential for developing targeted public health strategies that address the unique challenges faced by this population, balancing their cultural heritage with the realities of modern American life. Further analysis and wider scope studies are necessary to explore the implications of these findings on health outcomes.

However, the observed outcomes should be interpreted within the context of patient selection. The enrichment for prior responders limits the generalizability to unselected post-TKI populations, including those with primary resistance.

The HEATR5B-ALK fusion is targetable by ensartinib, producing durable disease control and excellent tolerability. Comprehensive NGS and ALK IHC are essential for detecting rare actionable ALK variants.

The association between the docking predictions and clinical outcomes corroborates the utility of computational modeling for tailoring therapies, although the structural models provide mechanistic insight into drug efficacy against these rare mutations. The present integrated approach emphasizes the value of merging in silico methods into clinical decision-making to overcome the therapeutic uncertainty of uncommon oncogenic driver alterations.

P1, N=72, Not yet recruiting, Kyowa Kirin, Inc. | N=34 --> 72

P1, N=330, Recruiting, Pfizer | Trial completion date: Sep 2028 --> Jan 2029 | Trial primary completion date: Sep 2027 --> Jan 2028

P1/2, N=55, Not yet recruiting, Unicancer

This study suggests that LOT may originate from principal cells of the collecting duct and distal renal tubule. Morphologically, it is characterized by a nested growth pattern with stromal edema, and immunohistochemically, it shows positivity for CK7 and negativity for CD117. The consistent positive expression of L1CAM in this study serves as a useful complementary marker for the differential diagnosis of LOT from other morphologically similar eosinophilic renal tumors. Regarding molecular genetics, this study not only explored the characteristics of mTOR pathway gene mutations in LOT but also identified one case with non-mTOR pathway-related molecular alterations, providing new supplementary information for the molecular landscape of LOT. Considering the cellular origin and indolent biological behavior of LOT, these findings contribute to further refinement of the classification system and nomenclature for this type of tumor. Additionally, this study provides important case data supporting LOT in the Chinese population.

Alectinib is the first ALK inhibitor to show a consistent DFS benefit over chemotherapy in patients with resected early-stage ALK-positive NSCLC, regardless of disease stage per AJCC/UICC 7th or 8th edition, nodal status, or tumor size.

P3, N=838, Active, not recruiting, SWOG Cancer Research Network | Trial primary completion date: Jan 2027 --> Nov 2025

P2, N=10, Not yet recruiting, Shaare Zedek Medical Center